3-(2,6-二氯苯氧基)-1-丙炔 | 3598-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2,6-二氯苯氧基)-1-丙炔
• 英文名称: (2,6-Dichlorphenyl)-propargylether
• 英文别名: 1,3-Dichloro-2-(prop-2-yn-1-yloxy)benzene；1,3-dichloro-2-prop-2-ynoxybenzene
• CAS: 3598-66-1
• 化学式: C₉H₆Cl₂O
• mdl: MFCD00052717
• 分子量: 201.052
• InChiKey: HCGOBPUSIBTNRV-UHFFFAOYSA-N

物化性质

• 熔点：
  40-42°C
• 稳定性/保质期：

  在常温常压下保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2909309090

SDS

Name:	1 3-Dichloro-2-(prop-2-ynyloxy)benzene 97% Material Safety Data Sheet
Synonym:	3-(2,6-Dichlorophenoxy)prop-1-yn
CAS:	3598-66-1

Section 1 - Chemical Product MSDS Name:1 3-Dichloro-2-(prop-2-ynyloxy)benzene 97% Material Safety Data Sheet
Synonym:3-(2,6-Dichlorophenoxy)prop-1-yn

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3598-66-1	1,3-Dichloro-2-(prop-2-ynyloxy)benzene	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3598-66-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 42 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H6Cl2O
Molecular Weight: 201

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3598-66-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,3-Dichloro-2-(prop-2-ynyloxy)benzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3598-66-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3598-66-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3598-66-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2,6-二氯苯氧基)-1-丙炔 在 叠氮基三甲基硅烷 、 水 、 silver carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  双金属催化级联反应通过原位生成的2-叠氮基丙烯有效合成N-异丙烯基1,2,3-三唑

  摘要：

  据报道，双金属催化的级联反应可高产率地合成N-异丙烯基1,2,3-三唑。该反应涉及通过点击反应的C（sp 3）-OAr键裂解原位生成2-叠氮基丙烯，并具有广泛的底物范围，良好的官能团耐受性和容易获得的底物。

  DOI：

  10.1002/asia.201900402
• 作为产物：
  描述：

  2,6-二氯苯酚 、 3-溴丙炔 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3-(2,6-二氯苯氧基)-1-丙炔
  参考文献：
  名称：

  双金属催化级联反应通过原位生成的2-叠氮基丙烯有效合成N-异丙烯基1,2,3-三唑

  摘要：

  据报道，双金属催化的级联反应可高产率地合成N-异丙烯基1,2,3-三唑。该反应涉及通过点击反应的C（sp 3）-OAr键裂解原位生成2-叠氮基丙烯，并具有广泛的底物范围，良好的官能团耐受性和容易获得的底物。

  DOI：

  10.1002/asia.201900402

文献信息

• [EN] EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS<br/>[FR] POTENTIEL THÉRAPEUTIQUE ÉTENDU DANS DES ANTIMICROBIENS À NITROHÉTÉROARYLE
  申请人：UNIV CALIFORNIA

  公开号：WO2014205414A1

  公开（公告）日：2014-12-24

  Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to imidazole, thiazole, and furan derivatives and their use as therapeutic agents.

  本文披露了抗微生物化合物组合物、药物组合物及其使用和制备。一些实施例涉及咪唑、噻唑和呋喃衍生物及其作为治疗剂的用途。
• Discovery and biological evaluation of some (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety as potent xanthine oxidase inhibitors
  作者：Ting-jian Zhang、Song-ye Li、Wei-yan Yuan、Qing-xia Wu、Lin Wang、Su Yang、Qi Sun、Fan-hao Meng

  DOI：10.1016/j.bmcl.2017.01.049

  日期：2017.2

  A series of (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety were synthesized and identified as novel xanthine oxidase inhibitors. Among them, the most promising compounds 1h and 1k were obtained with IC50 values of 0.6 μM and 0.8 μM, respectively, which were more than 10-fold potent compared with allopurinol. The Lineweaver-Burk plot revealed that compound

  合成了一系列含有蒽醌部分的（1 H -1,2,3-三唑-4-基）甲氧基苯甲醛衍生物，并将其鉴定为新型黄嘌呤氧化酶抑制剂。其中，获得最有前途的化合物1h和1k的IC 50值分别为0.6μM和0.8μM，与别嘌呤醇相比，具有50倍以上的效力。Lineweaver-Burk图显示化合物1h充当了混合型黄嘌呤氧化酶抑制剂。SAR分析表明，对于抑制效力，苯甲醛部分比蒽醌部分起着更重要的作用。黄嘌呤氧化酶被1h显着抑制的基础 通过分子模型研究合理化。
• Thermische Umlagerungen von halogensubstituierten Aryl-propargyläthern
  作者：Nada Šarčevic̀、Janos Zsindely、Hans Schmid

  DOI：10.1002/hlca.19730560502

  日期：1973.7.18

  7-Chloro-2-chloromethyl-benzofuran (13) and 3, 8-dichloro-2 H-1-benzopyran (12) are the main products from the thermal rearrangement (230–260°) of 2, 6-dichlorophenyl propargyl ether (7). Compounds 17, 18 and 19 are also formed, but in much smaller amounts (scheme 2 and table 1). However, in the case of the bromo-compounds 8 and 9 the rearrangement products are the benzofuran derivatives 21 and 22

  7-氯-2-氯甲基苯并呋喃（13）和3，8-二氯2 H -1-苯并吡喃（12）是2，6-二氯苯基炔丙基醚的热重排（230-260°）的主要产物（7）。化合物17，18和19也被形成，但在更小的量（方案2和表1）。然而，在溴化合物8和9的情况下，重排产物是苯并呋喃衍生物21和22，其每分子少含一个溴原子（方案4）。
• Aglycone-focused randomization of 2-difluoromethylphenyl-type sialoside suicide substrates for neuraminidases
  作者：Hirokazu Kai、Hiroshi Hinou、Shin-Ichiro Nishimura

  DOI：10.1016/j.bmc.2012.02.001

  日期：2012.4

  potent inhibitor of neuraminidases, a hydrolase that is responsible for processing sialylated glycoconjugates, is a promising drug candidate for various infective diseases. The current study demonstrates that the use of an aglycone-focused library of 2-difluoromethylphenyl α-sialosides is an effective technique to find potent and selective mechanism-based labeling reagents for neuraminidases. The focused

  神经氨酸酶的选择性和有效抑制剂是负责处理唾液酸化糖缀合物的水解酶，是治疗各种感染性疾病的有希望的药物。目前的研究表明，使用以糖苷配基为中心的2-二氟甲基苯基α-唾液酸苷文库是一种有效的技术，可以找到针对神经氨酸酶的有效的，基于选择性机理的标记试剂。通过点击反应，由4-叠氮基-2-二氟甲基苯基唾液苷（2）和炔烃封端的化合物库构建了聚焦库。重点文库显示了两种神经氨酸酶，霍乱弧菌神经氨酸酶（VCNA）和人神经氨酸酶2（hNeu2），并为每种神经氨酸酶选择最有效的抑制剂。所选抑制剂的动力学分析表明，糖苷配基部分的修饰提高了K I值，相对于基本骨架而言，酶活性的t 1/2值几乎没有变化（2）。
• Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity
  作者：Yukiko Miyamoto、Jarosław Kalisiak、Keith Korthals、Tineke Lauwaet、Dae Young Cheung、Ricardo Lozano、Eduardo R. Cobo、Peter Upcroft、Jacqueline A. Upcroft、Douglas E. Berg、Frances D. Gillin、Valery V. Fokin、K. Barry Sharpless、Lars Eckmann

  DOI：10.1073/pnas.1302664110

  日期：2013.10.22

  Drugs against disease-causing microbes are among the major achievements of modern medicine, but many microbes show a tenacious ability to develop resistance, so they are no longer killed by available drugs. We show here for an important class of these drugs, represented by the common drug metronidazole, that broad modifications of the basic drug structure can improve drug activities against several clinically important microbes and unexpectedly overcome different forms of resistance. Several of these new drugs cure infections in animal models and are safe in initial toxicity evaluations. These findings provide reasons to develop this class of drugs as human medicines in the ongoing fight against disease-causing microbes.

  《意义》 药物对抗致病微生物是现代医学的重大成就之一，但许多微生物表现出顽强的耐药能力，因此它们不再被现有药物杀死。我们在这里展示了针对这些药物的一类重要药物（如常见药物甲硝唑）的广泛结构修改可以改善药物对多种临床重要微生物的活性，并意外地克服了不同形式的耐药性。其中几种新药物治愈了动物模型中的感染，并在初步毒性评估中表现安全。这些发现为在持续对抗致病微生物的斗争中将这类药物开发为人类药物提供了理由。

表征谱图